Designation of New Animal Drugs for Minor Use or Minor Species (MUMS) - Final Rule

Forms and Documents

Document	Type	Status	Availability
SS-- 0910-0605.doc	Supporting Statement A	Uploaded 2010-09-28	Available

IC Document Collections

IC ID	Collection	Type	Status	Form
181664	Reporting : Designation of New Animal Drugs for Minor Use and MInor Species ( MUMS) - Final rule		Modified

ICR Details

OMB Control No: 0910-0605	ICR Reference No: 201009-0910-009
Status: Historical Active	Previous ICR Reference No: 200708-0910-001
Agency/Subagency: HHS/FDA	Agency Tracking No:
Title: Designation of New Animal Drugs for Minor Use or Minor Species (MUMS) - Final Rule
Type of Information Collection: Extension without change of a currently approved collection	Common Form ICR:  No
Type of Review Request: Regular
OIRA Conclusion Action: Approved without change	Conclusion Date: 12/05/2010
	Date Received in OIRA: 09/30/2010
Terms of Clearance:

	Inventory as of this Action	Requested	Previously Approved
Expiration Date	12/31/2013	36 Months From Approved	12/31/2010
Responses	157	0	157
Time Burden (Hours)	1,362	0	1,362
Cost Burden (Dollars)	0	0	0

---

Abstract: Section 573 (21 U.S.C. 301), of the Minor Use and Minor Species Animal Health Act of 2004 (MUMS Act), established new regulatory procedures intended to make more medications legally available to veterinarians and animal owners for the treatment of minor animal species as well as uncommon diseases in major animal species. This legislation provides incentives designed to help pharmaceutical companies overcome the financial burdens they face in providing liminted - demand animal drugs. These incentives are only available to sponsors whose drugs are " MUMS - designated" by the FDA. Participation in the MUMS program is completely optional for drug sponsors. FDA published a final rule July 26, 2007 (72 FR 41010),that specifies the criteria and procedures for requesting MUMS designation as well as the annual reporting requirements for MUMS designee.

---

Authorizing Statute(s): US Code: 21 USC 301 Name of Law: null
  

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:
	Not associated with rulemaking

---

Federal Register Notices & Comments
60-day Notice:	Federal Register Citation:	Citation Date:
	75 FR 42094	07/20/2010
30-day Notice:	Federal Register Citation:	Citation Date:
	75 FR 59721	09/28/2010
Did the Agency receive public comments on this ICR? No

---

Number of Information Collection (IC) in this ICR: 1

IC Title	Form No.	Form Name
Reporting : Designation of New Animal Drugs for Minor Use and MInor Species ( MUMS) - Final rule

---

ICR Summary of Burden

	Total Approved	Previously Approved	Change Due to New Statute	Change Due to Agency Discretion	Change Due to Adjustment in Estimate	Change Due to Potential Violation of the PRA
Annual Number of Responses	157	157	0	0	0	0
Annual Time Burden (Hours)	1,362	1,362	0	0	0	0
Annual Cost Burden (Dollars)	0	0	0	0	0	0

Burden increases because of Program Change due to Agency Discretion: No

Burden Increase Due to:

Burden decreases because of Program Change due to Agency Discretion: No

Burden Reduction Due to:

Short Statement:

---

Annual Cost to Federal Government: $30,375

Does this IC contain surveys, censuses, or employ statistical methods? No

Is the Supporting Statement intended to be a Privacy Impact Assessment required by the E-Government Act of 2002? No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? No

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? No

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? No

Is this ICR related to the Pandemic Response? Uncollected

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 09/30/2010

---